Evidence map›Paper›PMID 38459361›Full record

ReviewMolecular biotechnology2025

FDA-Approved Chimeric Antigen Receptor (CAR)-T Cell Therapy for Different Cancers-A Recent Perspective.

R Thirumalaisamy, S Vasuki, S M Sindhu, T M Mothilal, V Srimathi, B Poornima, M Bhuvaneswari, Mohan Hariharan

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Targeting Adaptive and Innate Immune Responses with Covalent Aptamers.Journal of the American Chemical Society · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Oncology research · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

R ThirumalaisamyDepartment of Biotechnology, Sona College Arts and Science, Salem (Dt.), Tamil Nadu, 636005, India. tmalaisamy@gmail.com.ORCID http://orcid.org/0000-0003-3137-5895
S VasukiDepartment of Biotechnology, Sona College Arts and Science, Salem (Dt.), Tamil Nadu, 636005, India.
S M SindhuDepartment of Biotechnology, Sona College Arts and Science, Salem (Dt.), Tamil Nadu, 636005, India.
T M MothilalDepartment of Biotechnology, Sona College Arts and Science, Salem (Dt.), Tamil Nadu, 636005, India.
V SrimathiDepartment of Biotechnology, Sona College Arts and Science, Salem (Dt.), Tamil Nadu, 636005, India.
B PoornimaDepartment of Biotechnology, Sona College Arts and Science, Salem (Dt.), Tamil Nadu, 636005, India.
M BhuvaneswariDepartment of Biotechnology, Sona College Arts and Science, Salem (Dt.), Tamil Nadu, 636005, India.
Mohan HariharanCenter for Applied Research, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamilnadu, 602105, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the most prevalent diseases in the world, and their rate of occurence has been increased in recent decades. Current review article, summarizes the novel treatment options Chimeric Antigen Receptor-T (CAR-T) cell therapy for various cancers constitute a major health and development challenge, impacting every aspect of sustainable development quoted by goal 3 good health and well-being of UN sustainable goals. WHO estimates that 70% of cancer deaths occur in low- and middle- income countries (LMICs) by 2030, LMICs are expected to bear the brunt of the expected 24.1 million new cancer cases per year. This current review article focuses and discussed about CAR-T cell therapy for various cancers against most prevalent non-communicable disease cancer disease stipulated by WHO and UN sustainable goals. Three literature databases Google scholar, Science Direct, PubMed was utilized to search and collect CAR-T cell treatment options for different cancers published articles sources in between January 2000 and December 2023. There were a total of 18,700 papers found, with 48 of them being found to be eligible focusing various cancer treatment by CAR-T cells utilized for the study. Based on the information gathered, CAR-T cell therapy treating different cancers and their merit and its advantages in heal and improve certain cancers was also discussed in this review article with their detailed molecular mechanisms. This article also gives an insight to utilize CAR-T cell treatment protocols for rejuvenating cancer patient from such ruthless cancer disease condition thereby improving life span of cancer patients and eradication of disease in some cases.

Indexed as

Immunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenHumansT-LymphocytesReceptors, Chimeric AntigenCancerChimeric Antigen Receptor-T cell (CAR-T)NovelTherapeutics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.